At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 217 enrolled

Drug / intervention

bimagrumab +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02333331

NCT02333331Phase 2Completed

Compare CT.gov

A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)

Novartis Pharmaceuticals·interventional·Posted Jan 7, 2015·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating bimagrumab and placebo for Sarcopenia. Completed, enrolled 217 participants across 58 sites in 13 countries.

Detailed Summary

The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsSarcopenia

CountriesAustralia, Belgium, Czechia, Denmark, France, Germany, Japan, Russia, South Korea, Spain, Switzerland, Taiwan, United States

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartDec 2014

First PostedJan 2015

Primary CompletionJun 2018

Study CompletionJun 2018

TodayJul 2026

First PostedJan 7, 2015

Enrollment StartDec 9, 2014

Primary CompletionJun 26, 2018

Study CompletionJun 28, 2018

TodayJul 2, 2026

Enrollment to primary: 3.5 yearsPosted 11.5 years ago

Interventions

bimagrumabdrug

Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

placeboother

Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.